ABOUT

Pipeline specialized for Musculoskeletal Diseases

About US

ImmunoForge is expanding and diversifying clinical and non-clinical pipelines, focusing on novel drug candidates for rare musculoskeletal diseases.

  • Home
  • >
  • About
  • >
  • About US

Introduction

We have a profound belief that the better the treatment, the happier the patients.

Millions of patients are suffering from thousands of rare diseases and hundreds of new intractable disorders are diagnosed every year around the world. We can challenge the development of rare disease treatments with cutting-edge technology and a sense of mission and passion. Our motivation is to meet the unmet needs in patients with rare diseases with more tolerable and effective long-term treatment.

We aim to develop first-in-class global drugs with a high probability of success through detailed action plans in candidate selection, preclinical and clinical development, and product approval.

Cutting-edge science and technology are our raw materials, and experience and passion are our tools. We believe that our endeavours will provide a lifeline to those with potentially fatal diseases and enhance the quality of life for those living with chronic conditions. We would like to express our gratitude to all those who care and support us. Your support makes us more passionate. For a better world, we will work harder.

Thank you.

Management

Sung-Min AhnMD-PhD
Translational Scientist based on his knowledge and experience as MD.
Specialty
  • Cancer genomics
  • New Drug Development
Major
Experience
  • Prof. Dept. of Genome Medicine and Science, Gachon University
  • Director, Gacheon Institute of Genome medicine and Science, Gachon University Gil Medical Center
  • A SAB member, WIN Consortium for Personalized Cancer Medicine
  • An advisory member, IBM Oncology Data Innovation Council
  • MD, College of Medicine, Ajou University
  • Ph.D Univ. of Melbourne (Proteogenomics)
Kiho Chang CEO MBA
A Business Developer with extensive experience in the new drug development process.
Specialty
  • Biodrug Development
  • Global Business
Major
Experience
  • General manager of Bio division, Ahngook Pharmaceutical
  • Head of Bio division, LG Life Sciences
  • The research center, QC, Product development, Overseas business / Dong-A Pharmaceutical
  • MBA, Yonsei University
  • Bs. In Life Sciences, Sogang University
EunKyu Lee Chief Research Officer
  • Emeritus Professor, Department of Bio nano Engineering, Hanyang University
  • Vice President of Research at Gachon University
  • Head of Basic Research Division, Korea Research Foundation
  • Senior Member of the National Academy of Engineering of Korea
Jongwon Kim Chief Technology Officer
  • Osong Medical Innovation Foundation, New Drug Development Center
  • Monarch Life Science LLC
  • Indiana University School of Medicine
  • Pusan National Univ. Ph.D Molecular Biology
Jim Ballance Chief Science Officer/President of US branch
  • PhaseBio Pharmaceuticals Inc.
  • BioRexis Pharmaceutical Corp.
  • Aventis Behring LLC
  • Delta Biotechnology Ltd.
Sang-Dae Kim Chief Financial Officer
  • Hyundai Mobis
  • Korea Technology Investment
  • YG Plus
Hyun Jin Kwon Director/Non-Clinical Development
  • Medical Research Institute, Gacheon University Gil Hospital
  • SNU Medical Research Center
Minhee Song Director/Clinical Development
  • Chong Kun Dang, CKD
  • Samsung Bioepis
  • Covance
Heesung Jeon Senior Managing Director/Strategy and Planning
  • Osong Medical Innovation Foundation
  • Korea Institute of Science & Technology Evaluation and Planning
Kyu-Hyun Han Director / Business Development
  • Hugel Inc.
  • Aestura Inc.
  • ChaBio&DiosTech Inc.

Scientific Advisory Board

Yasuda Shinsuke MD, Ph.D
  • Professor
  • Dept. of Rheumatology,Tokyo Medical and Dental University(TMDU)
Michael Hanna MD
  • Director (Prof.)
  • UCL Queen Square Institute of Neurology
Linda Greensmith Ph.D
  • Dept. Head of Neuromuscular Diseases
  • UCL Queen Square Institute of Neurology
Hee-Sook Jun Ph.D
  • Gachon University College of Pharmacy (Prof.)
  • PF1801 Sarcopenia use patent developer
  • Animal research cooperation
Young chul Choi MD, Ph.D
  • Neurology, Yonsei University College of Medicine (Prof.)
  • PF1801 Dysferlinopathy cooperation
Eun Young Lee MD, Ph.D
  • Department of Rheumatology, Seoul National University Hospital (Prof.)
  • PF1801 PM Clinical Study Protocol Leading

Organizational Chart

  • Co-CEO
  • CFO
  • CDO
  • CRO
  • CTO
  • President
    (US)
  • New
    Bio-Drugs
  • Non-clinical
    Development
  • Clinical
    Development
  • Manufacturing
    / CMC
  • Business
    Development
  • Strategy &
    Planning
  • Business
    Support
New
Bio-Drugs
  • Research on new bio-drugs
  • Bio process and formulation
  • PK·ADA analysis
Non-clinical
Development
  • Effectiveness and ADME
  • Toxicity tests
  • New Synthetic Drug research
  • IP
Clinical
Development
  • Clinical trials
  • Clinical RA
  • IND submission
  • Response to MFDS
Manufacturing
/ CMC
  • CM regulation
  • Clinical sample production
Business
Development
  • Global business development
  • Mid- to long-term business strategy
  • Open innovation
Strategy &
Planning
  • Public relations
  • Marketing
  • Human resources
Business
Support
  • Finance & accounting
  • IPO, government projects
  • Internal relations, general affairs

History

Leap to Global bio venture company by securing new-drug development technology
2022
Apr

PF1801 DMD FDA P2a IND approval

2021
Oct

Material Transfer Agreement with Korea Univ (pH-sensitive Fc variant)

PF1801 receives US FDA ODD for PM indication

Sep

Company Headquarters relocation (Seoul National Univ > Gasan Digital Complex)

Aug~Sep

21 billion KRW (approx. 19M USD) raised for Series-B funding

Apr

Selected for Industrial-Academic Research Institute Collaboration Project (500 million KRW) (approx. 450K USD)

Jan

US Office established (Vice President Dr. Jim Ballance)

Underwriter selection (KB Securities)

2020
Dec

PF1801 receives US FDA ODD for DMD indication

Aug

Raises 6 billion KRW for Bridge funding (approx. 5.4M USD)

Selected for The Ministry of Trade, Industry and Energy's global investment-linked technology development project (1.9 billion KRW) (approx. 1.6M USD)

Jul

Selected as a participant in the Kinase Inhibitor project of the Daegu Gyeongbuk Advanced Medical Industry Promotion Foundation.

Jun

DMD P2a Clinical trial IND submission to FDA

Apr

Selected as a participant in the Polymyositis project of the Ministry of Health and Welfare. (1.6 billion won) (approx. 1.3M USD)

Mar

Signed a technology transfer contract with Ewha Woman's University (anti-OSCAR, antibody for osteoarthritis treatment)

2019
Oct

Selected as a participant in stepping stone project of Ministry of SMEs and Startups (PF1802)

Jul

Selected as a participant in a new drug development project of Korea Drug Development Fund (KDDF) 3 billion KRW (approx. $2.7M)

Mar
Contracted PF1801 global licensing agreement with PhaseBio, USA
Feb
Raised 5 billion KRW through Series-A funding (approx. 4.5M USD)
2018
Aug

Selected as a participant in stepping stone project of Ministry of SMEs and Startups (RET inhibitor)

Jul

Selected as a participant in the candidate substance optimization project of the Daegu-Gyeongbuk New Drug Development Center (KF1601)

Jan

Transfer Kinase Inhibitors library patented technology (Daegu Gyeongbuk Advanced Medical Industry Promotion Foundation / Gachon University)

Venture certification & Corporate Research Institute certification

2017
Dec

Government TIPS program agreement
(development of sarcopenia treatment) (PF1801)

Attracted investment from Hugel

Sep

Acquired a patent for sarcopenia (Gachon University)

May

Company Established